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Summary: Chemotherapy studies were undertaken in 180 patients with tuberculous meningitis. 
They were treated for 12 months withlof3 regimens: the first consisted of streptomycin, isoniazid 
and rifampicin daily for the first 2 months, followed by ethambutol plus isoniazid for 10 months; 
in the second, pyrazinamide was added for the first 2 months, and in the third, rifampicin was re-
duced to twice weekly in the first 2 months. In the first regimen alone, streptomycin was also given 
twice weekly from the third to the sixth month. Steroids were prescribed for all the patients in thc 
initial weeks of treatment. Approximately 50% of the patients were aged less than 3 years. On 
admission, 13%of the patients were classified as stage 1,77% as stage Hand 9% as stage III. Cere-
brospinal fluid (CSF) culture results were available for all the 180 patients and M. tuberculosis was 
isolated in 59 (33%). CSF smear results for acid fast bacilli were available only for the 103 patients 
admitted to the second and the third studies, and of these, in 60 (58%) the CSF was positive cither 
by smear or culture. 
The response to therapy was similar in the 3 studies. Despite administration of rifampicin for 
2 months, the mortality was high. In all, 27% of the patients died of tuberculous meningitis, 39% 
had neurological sequelae and 34% recovered completely. There was a strong association between 
i lu  stage on admission and the mortality rate, the deaths being highest in stage III. In the first 
study; when isoniazid was prescribed daily in a dosage of 20 mg/kg, 39 % of the patients developed 
jaundice however, when the dosage was reduced to 12 mg/kg, the incidence was only 16%. In the 
third study. where rifampicin was administered twice a week, the incidence of jaundice was low 
(5%). 
Introduction 
Meningitis is the commonest cause of death 
from tuberculosis in children. While combina-
tions of bactericidal and sterilising drugs like 
streptomycin, isoniazid, rifampicin and 
Pyrazinamide have been found to be highly 
effective in the treatment of pulmonary 
tuberculosis in adults, information about the 
value of these drugs in the treatment of 
tuberculous meningitis is limited. Three 
consecutive studies were therefore undertaken by 
the Tuberculosis Research Centre, Madras, in 
collaboration with the Institute of Child 
Health and Hospital for Children, Madras, to 
evolve suitable regimens for the treatment of 
tuberculous meningitis in children. Preliminary 
findings of part of the first study have already 
been published (Rama-chandran, 1980). A 
complete report of the 3 studies, including a 1 
year follow-up, is presented here. 
Plan and conduct of the studies 
In all, 180 patients with tuberculous menin-
gitis, aged between 1 and 12 years, who had 
received not more than 4 weeks of anti-tuber- 
culosis treatment and had no evidence of renal 
or liver disease, were admitted to the 3 con-
secutive studies. The majority of patients be-
longed to the lower socio-economic groups and 
came from the urban and semi-urban areas of 
Madras city, while a few came from rural areas. 
On admission, 53 % of the patients were aged 
less than 3 years [fable 1]; only 17% were aged 
5 years or more. Approximately half (53%) 
were males. 
Criteria for diagnosis 
The diagnosis was based on clinical symp-
toms and signs, notably fever, vomiting, irri-
tability, apathy, refusal to play, anorexia, 
constipation, well-marked meningeal signs, 
impaired consciousness, coma and widespread 
paralysis. The cerebrospinal fluid [CSF] findings 
were also taken into consideration. 
Investigations 
A 1 TU Mantoux test (PPD batch RT 23 
with Tween 80) was done on admission, and 
read at 2 or 3 (occasionally 4) days. Antero-
posterior chest radiographs were taken on ad-   
*This paper is also being published in the Tubercle (.London) by agreement with the editors. 
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Stage I: Patients were conscious and had 
mainly non-specific symptoms, with or without 
signs of meningeal irritation, but no focal neu-
rological signs. Diagnosis was established mainly 
on CSF findings. 
mission and at the end of treatment. 
Urine tests for acetylisoniazid, bile salts, 
bile pigments, urobilinogen. albumin 
and deposits were done on admission and 
at 1 and 2 months; then, after, tests for 
albumin and acetylisoniazid were done 
every month. Estimations of serum 
aspartate, alanine amino-transferase and 
alkaline phosphatass activities, serum 
bilirubin, blood urea, plasma creatmine, 
haemoglobin, blood platelet count and 
total and differential white blood cell 
counts were done on admission, at 1 and 2 
months and the end of chemotherapy. 
Biochemical, eytological and bacterio-
logical examinations of the CSF were done 
on admission and every 2 weeks during the 
first 2 months and subsequently every 
month until the results were normal. 
Stage II: Patients were menially confused 
and/or had neurological signs. 
Stage III: Patients were comatose and had 
gioss neurological signs. 
Chemothcrapcutic regimens 
All patients were to be treated for 12 months. 
The regimens in the 3 studies were as follows: 
First study: Regimen 1: 2SHR/4S2EH/6EH: 
Streptomycin plus isoniazid plus rifampicin daily 
for 2 months, followed by ethambutol plus isoniazid 
daily supplemented by streptomycin twice a week 
for 4 months, followed by etham-butol plus 
isoniazid daily for 6 months. 
Second study: RegimenIII: 2SHRZ/IOEH: 
Streptomycin isoniazid plus rifampicin plus 
pyrazinamide daily for the first 2 months, fol-
lowed by ethambutol plus isoniazid daily for 
10 months. 
Third study: Regimen  III: 2R2SHZ/IOEH: 
Streptomycin plus isoniazid plus pyrazinamide 
dully and rifampicin twice a week for the first 2 
months, followed by ethambutol plus isoniazid 
daily for 10 months 
The   streptomycin  dosage   was   40  mg/kg body-
weight, rifampicin 12 mg/kg, ethambutol 17.5 
mg/kg and pyrazinamide 30 mg/kg. The first 
28 patients received  isoniazid in a daily dosage 
of 20 mg/kg, a dose used by most paediatricians 
for the treatment   of   tuberculous meningitis. 
However, a substantial proportion of the 
patients developed jaundice during the initial 
phase  of treatment with isoniazid and 
rifampicin.     Consequently,     the   dosage   of 
isoniazid was  reduced   to 12  mg/kg  and this 
dosage was prescribed to patients admitted to 
the second and third studies, also. In addition to 
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months of treatment. Those who were discharg-
ed during the first 2 months attended as out-
patients daily for chemotherapy until they 
completed 2 months. After 2 months the patients 
attended twice or once a week (or once in 15 
days if they lived outside Madras) to collect a 
supply of drugs. Their medication was fully 
supervised on the days they attended. Progress 
was assessed mainly by monthly clinical exa-
mination including a detailed neurological exa-
mination, and if indicated, a CSF examination, 
The patients were followed up for 12 months 
after completion of therapy. 
Surgery 
Patients clinically diagnosed to have deve-
loped hydrocephalus were investigated, and 
surgery (ventriculo-peritoneal shunt) was per-
formed, if indicated. 
Bacteriological   procedures 
CSF specimens were examined by fluore-
scence microscopy and cultured on Lowenstein-
Jensen medium with and without pyruvate, a 
selective 7H11 medium with antibiotics and 
liquid Kirchner medium [Allen et al, 1983]. 
Tests of sensitivity to streptomycin, isoniazid 
[Tuberculosis Chemotherapy Centre, Madras 
1960], rifampicin [Tuberculosis Research Centre, 
Madras 1983] and ethambutol [Subbammal et 
al, 1978] were performed. All positive cultures 
were identified [Marks. 1976 and Venkataraman 
et al, 1977]. 
Definitions of drug resistance 
Streptomycin:  A resistance rat io (RR) 
of 8 or more on 1 culture, or 4 followed by 8 
or more on a repeat test. 
Isoniazid : (a) Growth (defined as 20 colo-
nies or more) on 1 mg/1 or a higher concentra-
tion, or growth on 0.2 mg/1 followed by the 
same result on a repeat test. 
Rifampicin ; Growth on 64 mg/1 
Ethambutol; Growth on 4 mg/1. 
Results 
In all, 180 patients were admitted to the 3 
studies. Of these, 77 patients were treated with 
regimen I (first study), 29 with regimen II 
(second study) and 74 with regimen III (third 
study). A tuberculin test with 1 TU yielded an 
induration of 10 mm or more in 50% of the 
patients. In all, 84 (47%) patients had a history 
of contact with a known case of pulmonary 
tuberculosis and 99 (55%) had. an abnormal 
chest radiograph suggestive of pulmonary 
tuberculosis. On admission, 24 (13%) patients 
were classified as stage I, 139 (77%) as stage Il 
and 17 (9%) as stage III. There was a sugges-
tion that the stage of the disease on admission 
was related to the age. Thus, the proportion 
of patients with stage II or stage HI disease was 
115 (92%) of 125 in children aged 3 years or 
less compared with 41 (75%) of 55 in those aged 
4 years or more (P<0.01). A CSF protein 
value of more than 40 mg/100 ml on admission 
was observed in 96% of the patients. The nu-
tritional status of the patients was very poor. 
Using growth standards set up by the Indian 
Council of Medical Research (Reddy et al 1976). 
only 2% of the patients were considered nor-
mal, while 64%, had mild to moderate mal-
nutrition and 34% severe malnutrition, based on 
deficit in weight for age [I.C.M.R. 1972]. 
CSF smear results for acid fast bacilli were 
available for the 103 patients in the second and 
third studies only. Of these, in 24 (23 %) smear 
alone was positive, in 12 (12%) both smear 
and culture were positive and  in 24 (23%) 
culture alone was positive. Thus in the 103 pa-
tients for whom both smear and culture results 
were available, the diagnosis was bacteriologi-
cally confirmed in 58%. Of the 180 patients, 
M.   tuberculosis  was   isolated   from   the   CSF 
in 59 (33%) patients, 9 of 24 stage 1, 43 of 139 
stage II and 7 of 17 stage HI, the proportions in 
the different stages being similar. Of these 59, 
the culture was positive on admission in 46 
patients, within 2 months in 11 and at 4 and 8 
months in 2. Sensitivity test results for strepto-
mycin, isoniazid and rifampicin were available 
for 56 patients and for ethambutol in 48 patients. 
The cultures were resistant to streptomycin in 
1 (2%), to isoniazid in 3 (5%), to ethambutol 
in 1(2%) and to both streptomycin and iso-
niazid in 9 (16%). All the cultures were sensi-
tive to rifampicin. 
Response to treatment 
Of the 180 patients admitted to the three 
studies, 3 died of non-tuberculous causes and 21 
were discharged against medical advice before 
completing the therapy (see page 61). On follow 
up of these discharges, 7 were reported to have 
died within I week of discharge. Since the gene-
ral condition of all the 7 was very poor and the 
cause of death was most likely to be tuberculous 
meningitis, they were included in the analysis. 
The analysis of response to treatment was there-
fore based on 163 patients. 
The neurological, sequelae were classified as 
follows: Mild residual damage implied such 
sequelae as hyperactivity, irritability, mild per-
ceptual defects and limited motor impairment 
such as facial paresis or monoparesis. Moderate 
residual damage included such defects as hemi-
paresis, involuntary movements and substantial 
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mental impairment Patients with severe residual 
damage usually remained unconscious and even 
if consciousness was regained, they were in-
capable of independent existence. 
Table II gives the response to treatment in 
the 3 studies. Ft can be seen that 27% of the 163 
patients died of tuberculous meningitis, 39% 
had neurological sequelae (including 7%, with 
severe sequelae) and 34% made a complete re-
covery, The results in the 3 studies were similar. 
Table III gives the response according to 
the stage of the disease on admission. There 
was a clear association between the stage on 
admission and tuberculous deaths, the morta-
lity being 9% for stage I patients, 25% for stage 
II and 73%’ for stage III. Conversely, 78% of 
stage I patients recovered fully, compared with 
 
 
29% of stage II and 7% of stage III. An interest-
ing finding was that, in both the stage I patients 
who died and. the one who had severe neurologi-
cal sequelae, M. tuberculosis was grown in CSF, 
the strains being resislant. to both strepto-
mycin and isoniazid. There- was no association 
between the age of the patient and tuberculous 
deaths (Table IV). 
Of the 44 deaths. 17 (39%) occurred in the 
first week, 7 being from amongst the 15 stage 
III patients (Table V). In all. 29 (66%) died within 
4 weeks, 5 ( I I  %) in the second month, 4(9%} 
in the third month, 4(9%) between the fourth 
and the sixth month and 2 (5%) between the 
seventh and the twelfth month. The last avail-
able CSF result was biochemically abnormal in. 
41 of the 44 (and bacteriologically positive in 
11). The other 3 patients, who died in the fifth,. 
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TABLE IV 
Tuberculous deaths related to age on admission 
 
Age( years) No. of 
Patients 
TB deaths 
  No. °/ 
 
I— 49 16 33 
2— 37 8 22 
3 _  29 7 24 
4— 21 6 (29)* 
5 _  . 12 4 (33) 
6— 9 2       
7— 2 0  
    
8— 3 1 (20) 
9— 1 0  
Total : 163 44 27 
*Figures in brackets indicate percentages based on a 
total fewer than 25. 
seventh and ninth months had severe neurological 
sequelae with normal CSF findings. 
There was no association between drug 
resistance and response to treatment but the 
numbers were small (Table VI). 
Complications while on therapy 
Hydrocephalus: Fourteen patients (2 stage 
1,10 stage II, 2 stage III) were suspected of 
having developed hydrocephalus. Of these, 1 
died before investigations could be carried out 
and in 5, permission for investigations was 
refused. Of these 5, 3 died (in the fourth, seventh 
and ninth months), while the remaining 2 had 
moderate and severe neurological sequelae 
respectively at the end of chemotherapy. The 
diagnosis of hydrocephalus was confirmed in the 
remaining 8, and 7 of these underwent surgery, 
a ventriculoperitoneal shunt (3 in the second, 
1 in the third, and 3 in the twelfth month of 
treatment). At the end of chemotherapy 1 
(stage J) of the 7 had complete recovery, 3 (I 
stage 1, 2 stage II) had moderate sequelae, 2 
(both stage II) had severe sequelae and 1 (stage 
III) had died of tuberculosis. The eighth pa-
tient (stage 11), who did not have surgery, was 
reported to be alive at 24 months with mild 
sequelae. 
Blindness and optic disc changes ; Sixteen 
patients developed varying degrees of pallor of 
the optic discs while on treatment (5 while re-
ceiving isonizaid plus ethambutol). Six of these 
died before completing the treatment. The re-
maining 10 recovered and had normal fund us 
findings and vision at 24 months. 
Twelve patients developed optic atrophy with 
blindness (7 during treatment with ethambutol 
plus isoniazid) which persisted until the end of 
chemotherapy. On follow up, 7 patients had 
died and the remaining 5 continued to have 
optic atrophy and blindness at 24 months. 
Four patients had developed cortical blind-
ness during the first month of therapy; all of 
TABLE V Interval between admission and 
death, according to stage of disease on admission 
 
Stage of disease No. in Tuberculous deaths   
 analysis 
  Total              Week of treatment Month    of treatment  
  1             2             3 4       2        3 4 - 6  7-12 
1 23 2 1 0 0  0 0 0 1  0 
II 125 31             9             4             3 3 4 4 3  I 
III 15 11              7             2             0 0 1 0 0  1 
All 163 44          17            6            3 3 5 4 4  2 
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TABLE VI  
Culture and sensitivity results related to response to  treatment 
Initial culture/sensitivity findings 
Culture negative 
Sensitive to S, H and R 
Resistant to S,H or SH 
Sensitivitv test result not available 
 
Total TB death 
No.              % 
Complete 
No. 
Recovery 
% 
108   30             28 40 37 
39@   8               21 12 31 
13*   5              (38)** 3 (23) 
  3   1              (33) 0 (0) 
 
@ 1 patient had resistance to ethambutol alone. 
*Of these. 1 had resistance to streptomycin, 3 to isoniazid and 9 to both  drug 
**Figures in brackets indicate percentages based on a total fewer then 25. 
them regained  their vision by the  end of 4 
months. 
Of the 12 patients (aged between U—7 
years) who developed ocular complications dur-
ring treatment with ethambutol plus isonlazid. 
in the first 9, treatment with elhambutol was 
continued since it was considered that the prob-
lem was unrelated to the drugs. However, in the 
subsequent 3 patients, to be on the safe side, 
ethambutol was discontinued and PAS substi-
tuted. 
In the remaining 20 patients, who developed 
the ocular complications in the first 2 months of 
therapy with streptomycin, isoniazid and rifam-
picin, ethnambutol was given in the continua-
tion phase. 
Discharge against medical advice 
In all, 21 patients were discharged against 
medical advice before completion of treatment, 
15 in the first phase of therapy and the remaining 
6 subsequently. 
Of the former 15. 2 could not be traced. 
Twelve patients were reported to have died; 7 
within 1 week of discharge, 1 in the second 
week, 1 in the third week, 1 in the second month, 
1 in the third month and the last, 6 months 
after discharge. The last 2 patients had received 
anti-tuberculosis treatment from other sources 
after discharge. The thirteenth patient (stage I 
on admission), whose condition was good at the 
time of discharge, was found to be alive 24 
months after admission, with no sequelae. 
Of the remaining 6 patients (all stage II), 
3 were discharged during the third month (on 
follow-up, 2 had died within 2 months of dis-
charge and 1 was alive with moderate sequelae 
at 24 months) and 2 during the fourth month 
(on follow-up, 1 had. severe sequelae and the 
other could not be traced). The sixth patient, 
who was discharged in the sixth month, was 
reported to have died 6 months after discharge: 
the cause of death may not; have been connect-
ed with meningitis, as she had very good clini-
cal improvement and the CSF findings were 
normal at the time of discharge. Death was 
attributed to tuberculous meningitis in the 
others. 
Non-tuberculous deaths 
Three patients (all stage II) died from non-
tuberculous causes. One died in the fifth month, 
possibly due to an anaphytactic reaction after 
an injection given by a private practitioner for 
fever and respiratory infection. The other 2 
died during the ninth month: the first due to 
diarrhoea with dehydration; the second deve-
loped vomiting of sudden onset and died at 
home the next day. Since the clinical improve-
ment was substantial and the last available cere-
brospinal fluid findings were normal, the cause 
of death is unlikely to have been tuberculosis in 
either. 
Adverse reactions 
This analysis is based on all the 180 patients 
admitted to treatment. 
Jaundice: This was the major problem in 
the first 2 studies. In all, 30 patients developed 
jaundice in the 3 studies, all except 1 during the 
first 2 months, most of them in the second and 
third weeks (Table VJI). 
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TABLE  VII 
Incidence of jaundice in the first 2 months* 
 
Week   of   onset   of jaundice Study Regimen                       INHdose           Total  
                                      (mg/kg)         patients 
Patients who 
developed jaun- -
dice 
1          2 3 4 5 6-8 
   No          %      
First 2SHR/4S2EH/6EH            20 28 11            39 1          4 5 0 1 0 
 2SHR/4S2EH/6EH             12 49 8           16 1          2 4 1 0 0 
Second 2SHRZ/10EH                   12 29 6            21 0         4 1 0 1 0 
Third 2R2SHZ/IOEH                  12 74 4             5 1          0 3 0 0 0 
All  180 29           16 3        10 13 1 2 0 
*One other patient (.first study) developed jaundice in the fifth month. 
In the first study, when isoniazid was ad-
ministered in a dosage of 20 mg/kg, the inci-
dence of jaundice was 39% of 28; when the 
dosage was 12 mg/kg, the incidence was much 
less, namely, 16% of 49. In the second study, 
where pyrazinamide (30 mg/kg) was added to 
streptomycin, rifampicin and isoniazid (12 mg/ 
kg), the incidence of jaundice was 21 % of 29. In 
the third study, the same drugs as in the second 
study were administered but rifampicin was 
given only twice a week; the incidence of jaun-
dice with this regimen was low, namely 5% of 
74. 
In the patients who developed jaundice, 
rifampicin (first study) or both rifampicin and 
pyrazinamide (second and third studies) were 
discontinued while the other drugs were conti-
nued. 
Of the 29 patients who developed jaundice 
during the first 2 months of therapy, 24 re-
covered fully, the liver function test results re-
turning to normal; however 6 of these patients 
died subsequently due to tuberculous meningitis. 
The other 5 had died while still jaundiced. Of 
these, 1 patient died on the day jaundice was 
noticed and a definite cause of death could not 
be determined; 2 died while recovering from 
jaundice with the serial liver function test values 
showing considerable improvement, and death 
was attributed to tuberculous meningitis, jaun-
dice being a complicating factor. The fourth 
patient had, in addition to tuberculous meningi-
tis, miliary tuberculosis, enteric fever and her-
pes, and died of he pa to-cellular failure. In the 
last patient, jaundice persisted up to the time 
of death, 10 days after terminating rifampicin 
and pyrazinamide; a diagnosis of viral hepa-
titis could not be excluded. 
Only 1 patient developed jaundice after 2 
months (in the fifth month) while on isoniazid 
and ethambutol, and was diagnosed as a case 
of viral hepatitis. This patient recovered fully 
with empirical treatment. 
Skin reactions : Two patients, 1 in the first 
and the other in the third study developed skin 
reactions, both in the first month of treatment. 
The first patient developed extensive morbiliform 
eruptions with crusting and exfoliation. Rifam-
picin was stopped and the patient recovered 
completely. The second patient developed vesi-
cular eruptions over the lower abdomen and 
groins. All anti-tuberculosis drugs were with-
held for i week and the patient recovered fully. 
The treatment was resumed uneventfully, 
Arthralgia: One patient in the second study 
developed swelling of the elbow and knee joints 
during the first month. Pyrazinamide was stopp-
ed and the swelling diminished during the next 
3 weeks. He could not be followed up further 
as he died of tuberculous meningitis. 
Treatment continued beyond 12 months 
Of the 163 patients in the analysis of efficacy, 
119 completed treatment. In 23 of these, anti-
tuberculosis treatment was continued beyond 12 
months for the various reasons given below. 
The extended period of therapy was 1-6 months 
in 12 patients, 7-12 months in 10, and 24 months 
in 1 patient. 
(a) CSF abnormality, surgery or neurologi-
cal complications: Anti-tuberculosis treatment 
was continued on the advice of neuro-surgeons in 
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9 patients of whom 5 underwent a ventriculo-
peritonea] shunt. Two others had only raised 
CSF protein values and in the remaining 2, the 
parents refused permission for investigations in 
! and surgery for hydrocephalus in the other. 
Of the 9 patients. 4 died in the thirteenth, four-
teenth, fifteenth and twenty-third months and 
all had severe sequelae with normal CSF findings. 
Considering the 5 patients with a raised CSF 
prolein value, in 3 the CSF values became 
normal, at the fifteenth, twenty-second and 
twenty-third months while in the other 2, the 
high values persisted until the twenty-fourth 
month. The neurological status of the 5 
patients alive at 24 months was as follows: 
I had severe sequelae. 2 moderate and 1 
mild, while the last patient recovered fully, 
(b) Persistence    of   abnormality    on    chest 
radiograph: In 72 of 119 patients who complet 
ed treatment, she chest radiograph was abnor 
mal on admission. At 12 months, the lesions 
had cleared completely in 47, while there were 
ealciftc lesions in 15; in 1 patient the radiograph 
could not be repeated. In the remaining 9 pa 
tients, the radiographic shadows did not clear 
completely. In 1 patient, who had a normal ra 
diograph  on admission,  an abnormality (en 
largement of the carinal  gland)  was   detected 
at the end of therapy. In this, and the 9 patients 
with  persistent  abnormality, anti-tuberculosis 
treatment was continued beyond  1  year. The 
CSF  became   biochemically  normal  and  bac- 
teriologically negative  in  all  the   72  patients 
during the course of the 12 months. 
(c) Spinal lesions: Two patients had spinal 
tuberculosis in addition to tuberculous meningi 
t is  (diagnosed on admission on one and detect 
ed in the sixth month in the other). In both, 
chemotherapy was prolonged on the advice of 
the orthopaedic surgeon. The CSF at the end 
of 12 months was normal biochemically as well 
as  bacteriologically  in both the patients.   At 
24 months, both the patients had made a comp 
lete   recovery. 
(d) Other   reasons: In    2   patients   it   was 
considered inadvisable to stop anti-tuberculosis 
treatment at the end of 1 year on account of 
severe respiratory infection in  1  patient with 
severe sequelae (the patient died, in the twenty- 
first month), and the detection of   pulmonary 
tuberculosis in one of the parents of the second 
(patient   was   alive   with   moderate   sequelae 
at 24 months), 
Status at 24 months 
There were 119 survivors at the end of 12 
months—12 with severe sequelae, 36 with mo-
derate sequelae, 16 with mild sequelae and 55 
with complete recovery. 
Of the 12 patients who had severe sequelae, 
5 died, in 6 the condition remained the same 
and I had improved (to moderate sequelae). Of 
the 36 patients with moderate sequelae, 3 died 
(2 of sequelae and I of non-tuberculous cause), 
17 showed no improvement in neurological 
status, 13 showed slight improvement, 1 
improved to mild sequoia-:, while the remaining 
2 recovered completely. Of the 16 patients with 
mild sequelae, the status remained the same in 
13. I showed slight, improvement and the re-
maining 2 recovered completely. In the complete 
recovery group of 55 patients, I died from a 
complication of typhoid fever (perforation of 
the gut) while the recovery was maintained in 
the remaining 54 patients. 
The survivors at the end of 24 months are 
being followed, up further. 
Discussion 
The results of the present studies show a 
direct relationship between the stage on ad-
mission and death from tuberculous meningitis, 
the proportions being 9% for stage I patients, 
25% for stage II and 73 % for stage III. Similar 
observations have been made by others (Smith 
1964 Sister Gabrial, 1979 and Girgis et al, 
1976, 1978). These results suggest that early 
diagnosis and initiation of therapy is more 
important than the choice of drug regimen. 
Ethambutoi has been used in the treatment of 
childhood tuberculosis in Ind-a [Mankodi et al, 
1970. Bhatia et al, 1975 and Dingley et al, 
1974]. In all these studies, the dosage employed 
was 25 mg/kg for 2-3 months followed by 
15 mg/kg, and the reported incidence of 
ocular toxicity was negligible. In a study 
comparing different ambulatory regimens for 
spinal tuberculosis in Korea, 45 children 
(aged between 1 and 15 years) were treated 
with ethambutol ((5-25 mg/kg) plus isoniazid 
daily for 9 or 18 months. All the patients 
were assessed monthly and tests for visual 
acuity, colour vision and macular thresholds 
and visual fields were undertaken. There was no 
evidence from any of the assessments in any 
patient of ocular toxicity due to ethambutol 
(unpublished data from MRC Working Party 
on Tuberculosis of the Spine—Personal com-
munication from Prof. Wallace Fox). A study 
by Leibold [1966] suggests that, on a short term 
basis it is safe to prescribe as much as 45 mg/kg. 
In the present series of studies, ethambutol was 
used in a dosage of 17.5 mg/kg, a dose unlikely 
to cause rctrobulbar neuritis. Opticochiasma-tic-
araehnoidids resulting in visual impairment 
or even blindness, with or without associated 
hydrocephalus, is a common complication of 
tuberculous meningitis. All 12 patients in the 
present studies who developed blindness with 
persistent optic atrophy had moderate to 
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severe neurological damage and this was most 
likely to have been, the cause of blindness. 
The American Thoracic Society [1969] has 
recommended the systemic administration of 
corticosteroids in the management of tuber-
culous meningitis, a view which is supported by 
others [Lincoln et al 1963 and Kocen, 1977]. 
In the present series of studies, steroids were 
administered to all the patients as a routine. 
Jaundice was a major problem in the first 2 
studies, where daily therapy was given. The 
incidence was 39% in study I with isoniazid 20 
mg/kg and 16% when the dose was reduced to 
12mg/kg, and 21 % in study II where pyruzina-
mide 30 mg/kg was added to the regimen. Be-
cause of this high incidence of jaundice, in study 
III rifampicin was given only twice a, week ins-
tead of daily during the first 2 months and the 
incidence fell to 5 %. The above findings suggest 
that the use of daily rifampicin (12 mg/kg) with 
a high dose of isoniazid (20 mg/kg) causes a 
high risk of hepatotoxicity in children with tuber-
culous meningitis. The addition of pyrazina-
mide did not appreciably alter the incidence of 
heputotoxicity; a similar conclusion was re-
ported by Girling [1978] titter an extensive 
review of the literature. The rhythm of 
administration of rifampicin appeared to play 
a role, as regimens containing daily rifampicin 
carried a greater risk of hepatic toxicity than 
the regimen where it was given intermittently. 
Although the present series of studies were non-
concurrent and conclusions call for caution, 
similar results observed in studies from this 
Centre on patients with spinal and pulmonary 
tuberculosis [Parthasarathy et al, 1986] support 
the above deductions. Other factors that could 
have contributed to the high incidence of jaun-
dice in children with tuberculous meningitis 
have been dealt with by Parthasarathy and 
others [1986]. 
In conclusion, the results of the 3 studies 
show that, despite use of rifampicin-containing 
regimens, the mortality was high, especially in. 
stages II and III, while the prognosis was good 
in stage I. This emphasises the need for early 
diagnosis and prompt treatment. The combina-
tion of isoniazid 20 mg/kg and rifampicin 12 
mg/kg was associated with unacceptable levels 
of hepatotoxicity. Our findings suggest that, in 
view of the low hepatotoxicity, the third re-
gimen consisting of 2 months of daily strepto-
mycin, isoniazid and pyrazinamide plus twice 
weekly rifampicin followed by 10 months of daily 
ethambutol and isoniazid is a suitable regi-
men. It is also noteworthy that there were no 
relapses during the follow-up period, indicat-
ing that regular therapy for 12 months is ade-
quate for the treatment of tuberculous menin-
gitis. 
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